Doximity (DOCS)

Is still too expensive. Their last quarter wasn't that good. 

A high-growth company that last reported a bad, unfathomable and surprising miss.

DOCS has erased earlier gains from its last earnings report, amid the market drawdown, but it continues to be on a long-term uptrend, and forward sales and earnings estimates are strong. Analyst estimates have been trending higher in the past year, margins have been expanding, and it generates decent cash flows. It has a good balance sheet, but it is not cheap at 38X forward earnings. For a long-term investor, we would be comfortable holding here given its fundamental strength. 
Unlock Premium - Try 5i Free

Up 38% since IPO in fall 2021. Shares got killed last year during inflation and rate hikes. Has since rebounded. It's been a round trip. Their last report was solid, but guidance was ugly, given a delay in their new telemedicine product given regulatory interference. But they've beaten every quarter. Pricey at 47x PE 2023 but are profitable.